Buscar
Nkarta Inc
NKTXAñadir a la lista de seguimiento
2.090USD
-0.060-2.79%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
149.53MCap. mercado
PérdidaP/E TTM
Más Datos de Nkarta Inc Compañía
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
Información de Nkarta Inc
Símbolo de cotizaciónNKTX
Nombre de la empresaNkarta Inc
Fecha de salida a bolsaJul 10, 2020
Director ejecutivoHastings (Paul J)
Número de empleados157
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 10
Dirección1150 Veterans Boulevard
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Teléfono19254071049
Sitio Webhttps://www.nkartatx.com/
Símbolo de cotizaciónNKTX
Fecha de salida a bolsaJul 10, 2020
Director ejecutivoHastings (Paul J)
Ejecutivos de Nkarta Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Angela Thedinga
Ms. Angela Thedinga
Independent Director
Independent Director
--
--
Dr. George Vratsanos
Dr. George Vratsanos
Independent Director
Independent Director
--
--
Dr. Shawn Rose
Dr. Shawn Rose
Chief Medical Officer and Head of Research and Development
Chief Medical Officer and Head of Research and Development
--
-100.00%
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Paul J. Hastings
Mr. Paul J. Hastings
Chief Executive Officer, Director
Chief Executive Officer, Director
159.87K
-1.11%
Dr. Nadir Mahmood, Ph.D.
Dr. Nadir Mahmood, Ph.D.
President, Principal Financial Officer
President, Principal Financial Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Dr. Simeon J. George, M.D.
Dr. Simeon J. George, M.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Nkarta Inc?
Los cinco principales accionistas de Nkarta Inc son: Mr. Paul J. Hastings
¿Cuántas instituciones poseen acciones de Nkarta Inc (NKTX)?
A fecha de 2026Q1, 280 instituciones poseen acciones de Nkarta Inc, con un valor de mercado combinado de aproximadamente 58.52M, lo que representa el 82.11% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -25744153.00.